trial · primary record
Dinutuximab beta
High-risk GD2 Positive Ewing Sarkoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 18 |
| Primary completion | 2027-03-01 |
| Primary endpoint | GD2 Positivity |
| Registry ID | NCT06839703 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:23.976Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06839703
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.